RemeMG

Fall, 2025

Clinical Trial Open Enrollment

Dear MG Patient,

I am writing to let you know about the RemeMG Study, a clinical trial of a study drug for adults living with myasthenia gravis (MG). Current therapy for MG focuses on treating symptoms like muscle weakness, but these treatments do not always relieve symptoms and sometimes cause serious side effects. Because you are living with MG, we are asking you to consider taking part in the RemeMG Study.

What is the RemeMG Study?

The RemeMG Study will test how safe and effective a study drug called telitacicept is in adults with MG. The study drug targets the immune system, where the root cause of MG lies. The study lasts up to 84 weeks (a little over 1.5 years) and involves screening for up to 4 weeks followed by 2 treatment periods. In the 24-week first treatment period, participants will be randomly assigned (as if by the flip of a coin) to take either the study drug or placebo, which looks the same but has no active ingredients. During this time, participants have a 50% chance of receiving either one. Both are taken as weekly injections, some of which you can give yourself at home between visits to the study site.

If you complete the first treatment period, you may have the option of taking part in a 48-week extension, during which everyone will receive the study drug (no placebo). At the end of treatment (either the first period or the extension), participants will have 2 follow-up visits.

About 180 adults with MG are expected to join the RemeMG Study worldwide.

Who can take part?

You may be able to join the RemeMG Study if you:

- Are at least 18 years old
- Have been diagnosed with MG
- Do not have any other autoimmune diseases, such as rheumatoid arthritis or Sjogren's syndrome

There are other requirements for taking part. I would welcome the chance to talk with you about them to see if you may qualify.

Why should you take part in this study?

Taking part is voluntary, and deciding not to join will not affect your usual medical care now or in the future. Although there is no guarantee that you will directly benefit from taking part, you will help add to knowledge about treating MG. All participants will receive closely monitored medical care from a study doctor throughout the RemeMG Study.

What should you do if you are interested?

Please contact me if you would like to learn more. I will be happy to talk about details, your options, and the risks and benefits of participating in the study.

Sincerely,

Dr. Melanie Taylor (Principal Investigator)
Trinity Health Grand Rapids Hospital
Katie Schwass (Study Coordinator)
616-685-5437
Katherine.schwass@trinity-health.org